Brilinta tablet/contraindications: Difference between revisions
Created page with "__NOTOC__ {{Labeltemplate}} {{CMG}} {{AE}}{{JH}} ===Contraindications=== '''History of Intracranial Hemorrhage''' BRILINTA is contraindicated in patients with a history o..." |
No edit summary |
||
| Line 13: | Line 13: | ||
'''Active Bleeding''' | '''Active Bleeding''' | ||
BRILINTA is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage [[Brilinta tablet/warnings|Warnings]] | BRILINTA is contraindicated in patients with active pathological bleeding such as peptic ulcer or [[intracranial hemorrhage]] [[Brilinta tablet/warnings|Warnings]] | ||
and [[Brilinta tablet/ | and [[Brilinta tablet/adverse reactions|Adverse Reactions]]. | ||
'''Severe Hepatic Impairment''' | '''Severe Hepatic Impairment''' | ||
Revision as of 17:25, 21 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]
Contraindications
History of Intracranial Hemorrhage
BRILINTA is contraindicated in patients with a history of intracranial hemorrhage (ICH) because of a high risk of recurrent ICH in this population see Clinical Studies.
Active Bleeding
BRILINTA is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage Warnings
and Adverse Reactions.
Severe Hepatic Impairment
BRILINTA is contraindicated in patients with severe hepatic impairment because of a probable increase in exposure, and it has not been studied in these patients. Severe hepatic impairment increases the risk of bleeding because of reduced synthesis of coagulation proteins see Pharmacology.
Hypersensivity
BRILINTA is contraindicated in patients with hypersensitivity (e.g. angioedema) to ticagrelor or any component of the product see[[Brilinta tablet/Adverse Reactions|Adverse Reactions][1].
References
- ↑ "BRILINTA (TICAGRELOR) TABLET [ASTRAZENECA LP]". Retrieved 21 March 2014.